

Tentative Outline

Special/Thematic Issue for the Journal Current Topics in Medicinal Chemistry

Recent advances in Drug Discovery and Targeted Therapy

Guest Editor: Prof. Li-jie Zhao
Co-Guest Editor: Prof. Shuai Wang

Scope of the Thematic Issue:

Drug discovery and targeted therapy have advanced significantly in recent years, leading to improved treatment options for various diseases and conditions. This progress has been driven by advancements in technology, increased understanding of disease mechanisms, and the development of innovative therapeutic approaches. The advance of drug discovery and targeted therapy has significantly improved the treatment options available to patients. These advancements have led to more effective and precise therapies, reduced side effects, and improved patient outcomes. Nevertheless, despite a noteworthy surge in expenditures dedicated to drug research and development throughout this temporal span, the quantity of novel drug endorsements has not exhibited a substantial rise, thereby implying that the pursuit of therapeutic innovation has encountered heightened complexities. Hence, there is an urgent demand for expeditious advancement of novel methodologies in drug discovery and targeted therapy to foster strategic and technological breakthroughs in the field of medicinal chemistry. In the last decade, there has been a notable shift in the methodology employed for identifying pharmacologically significant compounds. The conventional serendipitous and trial-and-error approach has given way to a more intricate and multifaceted strategy, which has significantly enhanced the efficacy of drug discovery processes. We welcome high-quality in-depth/mini reviews or research articles for this Special Issue.

Keywords: New targets, New mechanisms, New strategies, Drugs repurposing, Privileged structures, Drug design, PROTACs, ADC drugs.

Sub-topics:

- Discovery of novel targets and elucidation of underlying mechanisms.
- Repurposing of drugs for alternative therapeutic indications.
- Utilization of privileged structures in the rational design of pharmaceutical agents.
- Advancements in expedited identification of potential drug candidates through innovative methodologies and strategies.
- Exploitation of proteolysis targeting chimeras (PROTACs) for targeted protein degradation.
- Design strategies for antibody conjugated (ADC) drugs.

Schedule:

- Complete Thematic issue submission deadline: **31st August 2024**

Contacts:

Guest Editor: Prof. Li-jie Zhao

Affiliation: The Rogel Cancer Center, Department of Internal Medicine, University of Michigan, United States

Email: lijiez1113@outlook.com

Co-Guest Editor:

Name: Prof. Shuai Wang

Affiliation: Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai, 200433, China;

Email: shuaiwang@fudan.edu.cn

Any queries should be addressed to support@benthamexecutiveeditors.com